Company / Revenue
NewAmsterdam Pharma Co N.V. Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$22.5M
FY2025
5-year range
$14.1M / $102.7M
FY2022-FY2025
Trend
-50.6%
vs FY2024
Sector context
#125 of 152
Health Care
What the data says
NewAmsterdam Pharma Co N.V.'s revenue of $23M is lower than 82% of companies in the Health Care sector (FY2025). Improved from $14M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025 with a 3-year CAGR of -39.7%.
Improved from $14M to $23M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -39.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 152This company $22.5M Sector average $4.5B
▼
-99.5% below sector average
Key checks
Key Insights
- 3-year CAGR of -39.7%, indicating a declining trend.
- In FY2025, revenue decreased 50.6% year-over-year.
- Ranks #125 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.5M | -50.6% |
| FY2024 | $45.6M | +223.4% |
| FY2023 | $14.1M | -86.3% |
| FY2022 | $102.7M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026